PD-1 blockade in anaplastic thyroid carcinoma
Journal
Journal of Clinical Oncology
Journal Volume
38
Journal Issue
23
Pages
2620-2627
Date Issued
2020
Author(s)
Capdevila J.
Wirth L.J.
Ernst T.
Aix S.P.
Ramlau R.
Butler M.O.
Delord J.-P.
Gelderblom H.
Ascierto P.A.
Fasolo A.
F?hrer D.
H?tter-Kr?nke M.L.
Forde P.M.
Wrona A.
Santoro A.
Sadow P.M.
Szpakowski S.
Wu H.
Bostel G.
Faris J.
Cameron S.
Varga A.
Taylor M.
Abstract
PURPOSE: -wild type disease. As part of a phase I/II study in patients with advanced/metastatic solid tumors, patients with anaplastic thyroid carcinoma were treated with spartalizumab, a humanized monoclonal antibody against the programmed death-1 (PD-1) receptor. METHODS: We enrolled patients with locally advanced and/or metastatic anaplastic thyroid carcinoma in a phase II cohort of the study. Patients received 400 mg spartalizumab intravenously, once every 4 weeks. The overall response rate was determined according to RECIST v1.1. RESULTS: -mutant patients and were durable, with a 1-year survival of 52.1% in the PD-L1-positive population. CONCLUSION: To our knowledge, this is the first clinical trial to show responsiveness of anaplastic thyroid carcinoma to PD-1 blockade.
SDGs
Publisher
American Society of Clinical Oncology
Type
journal article